/

Agios Pharmaceuticals, Inc.

AGIO US

AGIO USAgios Pharmaceuticals, Inc.

United States Composite

31.67

USD

-0.14

(-0.44%)

-6.33EPS Dil.

-5.01P/E

1.77BMarket Cap

Next Earnings

May 2

Held by Insiders

1.61%

Held by Institutions

107.75%

Short % of Float

13.05%

YTD Yield

33.42%

3Y Yield

-45.30%

Capital Structure

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

ST Debt

LT Borrowings

- -

LT Finance Leases

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

Market Capitalization

1,578

1,383

1,246

Working Capital

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

Total Current Assets

757

704

834

Cash, Cash Equivalents & STI

703

647

777

Accounts Receivable, Net

Inventories

Total Current Liabilities

Payables & Accruals

ST Debt

Deferred Revenue

- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

- -

92.86%

Net Income, GAAP

-104.91%

-151.07%

-51.72%

Free Cash Flow

-131.50%

-2.91%

-0.32%

Total Cash Common Dividend

- -

Total Equity

43.43%

27.49%

-26.34%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

- -

2022

2023

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

26.95

-1.41

-1.56

-1.74

26.55

2022

-1.74

-1.68

-1.49

0.66

-4.23

2023

-1.47

-1.51

-1.64

-1.72

-6.33

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Company Description

CEO: Mr. Brian M. Goff M.B.A.
Full Time Employees: 383
Sector: Healthcare
Industry: Biotechnology
Address: 88 Sidney Street Cambridge MA United States 02139
IPO Date: Jul 24, 2013
CIK: 0001439222
Website: www.agios.com
Business: Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Company News

Yahoo
7 days ago
Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024
Yahoo
14 days ago
Director Jacqualyn Fouse Sells Shares of Agios Pharmaceuticals Inc (AGIO)
Yahoo
16 days ago
Agios Publishes 2024 Environmental, Social and Governance (ESG) Report
Tipranks
16 days ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (ALNY), Gilead Sciences (GILD) and Agios Pharma (AGIO)
Yahoo
a month ago
We Think Agios Pharmaceuticals (NASDAQ:AGIO) Can Afford To Drive Business Growth
Yahoo
2 months ago
Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024

Company News

Yahoo
7 days ago
Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024
Yahoo
14 days ago
Director Jacqualyn Fouse Sells Shares of Agios Pharmaceuticals Inc (AGIO)
Yahoo
16 days ago
Agios Publishes 2024 Environmental, Social and Governance (ESG) Report
Tipranks
16 days ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (ALNY), Gilead Sciences (GILD) and Agios Pharma (AGIO)
Yahoo
a month ago
We Think Agios Pharmaceuticals (NASDAQ:AGIO) Can Afford To Drive Business Growth
Yahoo
2 months ago
Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024